J Thorac Oncol
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
Related Questions
The CROWN, ALTA, and ALEX trials showed improved efficacy with lorlatinib/brigatinib/alectinib vs crizotinib. How do you choose your first line therap...
New answer by Medical Oncologist at Virginia Cancer Specialists (VCS) Research Institute (March 20, 2025)
Tough question, and it boils down in my mind to lorlatinib vs brig or alectinib. For someone who’s younger and wants the therapy with the best outcome we know (though no...